Sensible Biotechnologies
ActiveUnlocking the next generation of mRNA medicines
About
The future of mRNA therapeutics is hampered by manufacturing challenges and unless solved, its exciting potential may never be realised. Sensible enables the next generation of mRNA medicines by turning living cells into factories producing abundant, highly stable and non-immunogenic mRNA in a scalable and cost-effective way.
Founders · 2
I am Miro, CEO and Co-Founder of Sensible Biotechnologies. We build a cell-based platform for cost-efficient and scalable production of high-quality mRNA to unlock next generation of mRNA medicines. My background is in computational modeling of biological systems and bioengineering. I have worked on developing Slovak national biosecurity policies - I am passionate about building biotech ecosystem in Eastern Europe. I studied Bioengineering at Imperial College London and Engineering at Oxford.
I am Marian, the Chief Scientific Officer and co-founder of Sensible Biotechnologies. We are building a new platform for cost-efficient and scalable manufacturing of high-quality mRNA. I have more than 9 year of experience in biochemistry and molecular biology, more specifically in cellular engineering and downstream processing. I am interesting in engineering cells to produce high-quality proteins and nucleic acids. I did my PhD in Biochemistry at the University of Oxford, UK.
Launch
mRNA. Made better.
Sensible Bio announces a platform that engineers living cells to produce high-quality, longer mRNA cost-effectively for vaccines and therapeutics, aiming to replace cell-free IVT methods. The approach combines cell engineering, computational biology, and precision fermentation to enable scalable, reduced-reagent mRNA production and address immunogenic dsRNA concerns.
From the original launch (Apr 2023) — may be outdated.
Formerly “Genbiotics”
Related startups
Enabling next generation medicines. A comprehensive platform and…
Elevated mRNA for transformative medicines.
